Alere first quarter net revenue increases to $582.5 million

Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended March 31, 2011.

Financial results for the first quarter of 2011:

  • Net revenue of $582.5 million for the first quarter of 2011, compared to $515.3 million for the first quarter of 2010.
  • Product and services revenues from our Professional Diagnostics segment were $409.8 million in the first quarter of 2011, compared to $336.2 million in the first quarter of 2010.  Recent professional diagnostics acquisitions contributed $30.8 million of incremental net revenue compared to the first quarter of 2010.
  • North American influenza sales increased to $19.5 million for the first quarter of 2011, compared to $2.3 million for the first quarter of 2010.
  • Excluding the impact of the change in North American influenza revenues, currency adjusted organic growth in our Professional Diagnostics segment was 6.9%.
  • Adjusted cash-basis gross margins were 55.8% for the first quarter of 2011, compared to 57.0% for the first quarter of 2010 and 55.3% in the fourth quarter of 2010.  Adjusted cash-basis gross margins from products and services in our Professional Diagnostics segment were 59.6% in the first quarter of 2011, compared to 60.1% in the fourth quarter of 2010.  Adjusted cash-basis gross margins from our Health Management segment increased sequentially from 47.6% in the fourth quarter of 2010 to 49.0% in the first quarter of 2011.
  • GAAP net income of $8.1 million attributable to common stockholders of Alere Inc. and respective net income per diluted common share of $0.09, compared to GAAP net income of $9.0 million attributable to common stockholders of Alere Inc. and respective net income per diluted common share of $0.11, for the first quarter of 2010.  
  • GAAP net income for the first quarter of 2010 included a gain of $19.6 million, net of costs to dispose ($12.0 million, net of tax), resulting from the disposition of our nutritionals business which was included in the first quarter of 2010 income from discontinued operations, or net income of $0.14 per common share.
  • Adjusted cash-basis net income per diluted common share of $0.61 for the first quarter of 2011, compared to adjusted cash-basis net income per diluted common share from continuing operations of $0.64, for the first quarter of 2010.
  • Adjusted free cash flow for the quarter was $58.2 million, reflecting adjusted cash flow from operations of $87.2 million, offset by capital expenditures of $28.9 million.

The Company's GAAP results for the first quarter of 2011 include amortization of $76.3 million, $6.4 million of restructuring charges, $5.8 million of stock-based compensation expense, $1.9 million of acquisition-related costs recorded in accordance with ASC 805, Business Combinations, a $1.9 million foreign currency loss associated with the settlement of an acquisition-related contingent consideration obligation and $1.4 million of expense recorded for fair value adjustments to acquisition-related contingent consideration obligations.  The Company's GAAP results for the first quarter of 2010 include amortization of $72.1 million, $8.0 million of restructuring charges, $7.6 million of stock-based compensation expense, a $2.8 million charge associated with the write-up to fair market value of inventory acquired in connection with the acquisition of Standard Diagnostics, Inc., $4.0 million of acquisition-related costs recorded in accordance with ASC 805, Business Combinations, $0.3 million of expense incurred in connection with the disposal of our nutritionals business, offset by $3.1 million of income recorded for fair value adjustments to acquisition-related contingent consideration obligations and a $1.9 million allocation of certain of the aforementioned charges to non-controlling stockholders. These amounts, net of tax, have been excluded from the adjusted cash-basis net income per diluted common share attributable to Alere Inc. for the respective quarters.

SOURCE Alere Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Alere Inc.. (2011, April 27). Alere first quarter net revenue increases to $582.5 million. News-Medical. Retrieved on September 18, 2019 from https://www.news-medical.net/news/20110427/Alere-first-quarter-net-revenue-increases-to-245825-million.aspx.

  • MLA

    Alere Inc.. "Alere first quarter net revenue increases to $582.5 million". News-Medical. 18 September 2019. <https://www.news-medical.net/news/20110427/Alere-first-quarter-net-revenue-increases-to-245825-million.aspx>.

  • Chicago

    Alere Inc.. "Alere first quarter net revenue increases to $582.5 million". News-Medical. https://www.news-medical.net/news/20110427/Alere-first-quarter-net-revenue-increases-to-245825-million.aspx. (accessed September 18, 2019).

  • Harvard

    Alere Inc.. 2011. Alere first quarter net revenue increases to $582.5 million. News-Medical, viewed 18 September 2019, https://www.news-medical.net/news/20110427/Alere-first-quarter-net-revenue-increases-to-245825-million.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Alere announces cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock